IMC (MC $30M) MEGA Blockbuster Candidate with P2 results soon=1000%++ Upside Potential

This unknown Goldmine has MONSTER Upside Potential if their Drug is successful in Phase 2 . The Market Cap of $30 Million is a big joke this stock should be over $2 per share right now and much much higher with positive P2 results . With Nasdaq Listing this undiscovered and brutally undervalued Stock has the potential to be the next Billion Dollar Company but i think there will be a Buyout before the Company can reach its full potential .  This Stock is a MUST Have at this ridiculous low share price . GL


Immuron (IMC.AX)

MarketCap:A$ 30.6 M
Cash: A$ 9.1 M
Price : 0.29

Immuron to start search for partner or buyer of fatty liver therapeutics in Q1 2017 - CEO
http://www.immuron.com/assets/Immur...er-of-fatty-liver-therapeutics-in-Q1-2017.pdf
Immuron could attract attention from large as well as second-tier pharma companies, Liquard said,citing as examples, companies, such as AstraZeneca[LON:AZN], Gilead[NASDAQ:GILD],Pízer [NYSEFE] and Sanofí [EPA:SAN].


leeuwenhoeck Analyse (February 2017)
http://nebula.wsimg.com/3acef70fe68...3D293B900048B2E3E&disposition=0&alloworigin=1


Based on an NPV valuation ,we believe that Immuron is substantially undervalued at the current share price of AUD 0.30 . We have increased our valuation calculation following a rerating of both its programs in NASH and CDI. Especially in NASH,the potential deal size has increased following recent activity in the area .In our view,the company´s current total value should be AUD 197 million, or AUD 1.92 per share compared to our previous calculation of AUD 75 million .This represents a substantial upside from the current share price .

Near Term Milestones

2017-Feb: NASH Phase II, Fully enrolled

2017 H1: Nasdaq listing and US Capital Raise

2017 H1: NASH Phase II Interim Results

2017 Q2: C.difficile –Manufacturing of Clinical Supplies Completed

2017 Q2: C.difficile –Initiation of Phase I/II

2017 H2: NASH Top line data Phase II

2018: ASH–Top line data Phase II

2018: C.difficile –Phase I/II results


Immuron’s platform technology is based on natural dairy-derived antibody products with low costs, a high safety profile, and multiple different regulatory pathways to market, minimizing risk while maintaining significant upside potential from prescribed drugs. Immuron is in phase II clinical trials for NASH (Australia and U.S.) and ASH (U.S.). NASH therapies are estimated at a $40 billion global market by 2025, and significant valuations have been afforded to companies in phase II trials for NASH. Intercept Pharmaceuticals had positive phase II results for NASH, leading to an increase in market cap from $1.5 billion to $6.6 billion.